GuruFocus Premium Membership

Serving Intelligent Investors since 2004. Only 96 cents a day.

Free Trial

Free 7-day Trial
All Articles and Columns »

Dorman Products Inc. (DORM) CFO Matthew S Kohnke sells 2,000 Shares

May 21, 2012 | About:
insider

insider

56 followers
CFO of Dorman Products Inc. (DORM) Matthew S Kohnke sells 2,000 shares of DORM on 05/17/2012 at an average price of $51.44 a share.

Dorman Products has a market cap of $898.9 million; its shares were traded at around $48.63 with a P/E ratio of 15.6 and P/S ratio of 1.7. Dorman Products had an annual average earning growth of 13.3% over the past 10 years. GuruFocus rated Dorman Products the business predictability rank of 4.5-star.

This is the annual revenues and earnings per share of DORM over the last 10 years. For detailed 10-year financial data and charts, go to 10-Year Financials of DORM.


CEO Recent Trades:



  • CEO, 10% Owner Steven L Berman sold 5,859 shares of DORM stock on 03/26/2012 at the average price of 48.59. Steven L Berman owns at least 1,989,906 shares after this. The price of the stock has increased by 0.08% since.
  • CEO, 10% Owner Steven L Berman sold 3,565 shares of DORM stock on 03/22/2012 at the average price of 46.43. Steven L Berman owns at least 1,995,765 shares after this. The price of the stock has increased by 4.74% since.
  • CEO, 10% Owner Steven L Berman sold 1,643 shares of DORM stock on 03/20/2012 at the average price of 46.63. Steven L Berman owns at least 1,999,330 shares after this. The price of the stock has increased by 4.29% since.
  • CEO, 10% Owner Steven L Berman sold 3,727 shares of DORM stock on 03/16/2012 at the average price of 45.8. Steven L Berman owns at least 2,000,973 shares after this. The price of the stock has increased by 6.18% since.
  • CEO, 10% Owner Steven L Berman sold 11,400 shares of DORM stock on 02/21/2012 at the average price of 46.71. Steven L Berman owns at least 1,991,933 shares after this. The price of the stock has increased by 4.11% since.

This is the insider trade history vs. stock price of DORM. For the complete insider trading history of DORM, click here.




Directors and Officers Recent Trades:



  • VP and General Counsel Thomas Joseph Knoblauch sold 500 shares of DORM stock on 05/17/2012 at the average price of 51.06. Thomas Joseph Knoblauch owns at least 2,755 shares after this. The price of the stock has decreased by 4.76% since.
  • SVP, Product Michael Kealey sold 694 shares of DORM stock on 05/16/2012 at the average price of 51. Michael Kealey owns at least 4,469 shares after this. The price of the stock has decreased by 4.65% since.
  • Director John F Jr Creamer sold 2,000 shares of DORM stock on 05/04/2012 at the average price of 49.33. John F Jr Creamer owns at least 16,225 shares after this. The price of the stock has decreased by 1.42% since.
  • VP and General Counsel Thomas Joseph Knoblauch sold 250 shares of DORM stock on 03/15/2012 at the average price of 47.49. Thomas Joseph Knoblauch owns at least 3,255 shares after this. The price of the stock has increased by 2.4% since.
  • Director Edgar W Levin sold 1,000 shares of DORM stock on 03/09/2012 at the average price of 45.68. Edgar W Levin owns at least 50,100 shares after this. The price of the stock has increased by 6.46% since.


For the complete insider trading history of DORM, click here.
  • CEO Buys, CFO Buys: Stocks that are bought by their CEO/CFOs.
  • Insider Cluster Buys: Stocks that multiple company officers and directors have bought.
  • Double Buys:: Companies that both Gurus and Insiders are buying
  • Triple Buys: Companies that both Gurus and Insiders are buying, and Company is buying back.

» Take a Free Trial of Premium Membership

About the author:

insider
GuruFocus - Stock Picks and Market Insight of Gurus

Rating: 5.0/5 (2 votes)

Comments

Please leave your comment:


Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK